Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Madrigal Pharmaceuticals, Inc. (MDGL : NSDQ)

• Company Description    Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. Number of Employees: 528

• Price / Volume Information    Yesterday's Closing Price: $314.64 Daily Weekly Monthly 20 Day Moving Average: 259,610 shares Shares Outstanding: 22.20 (millions) Market Capitalization: $6,986.04 (millions) Beta: -1.05 52 Week High: $377.46 52 Week Low: $200.63 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.86% 1.90% 12 Week 4.30% -12.27% Year To Date 1.97% -4.51%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 200 BARR HARBOR DRIVE SUITE 200 - WEST CONSHOHOCKEN,PA 19428 USA ph: 267-824-2827 fax: 781-274-8228 ir@madrigalpharma.com http://www.madrigalpharma.com

• General Corporate Information    Officers William J. Sibold - President and Chief Executive Officer Julian C. Baker - Chair of the Board Mardi C. Dier - Chief Financial Officer Rebecca Taub - Director Fred B. Craves - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 558868105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/06/25 Share - Related Items Shares Outstanding: 22.20 Most Recent Split Date: 7.00 (0.03:1) Beta: -1.05 Market Capitalization: $6,986.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-3.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-13.83 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 34.24% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 9.83 Price/Cash Flow: - Price / Sales: 22.01 EPS Growth vs. Year Ago Period: 55.01% vs. Previous Quarter: -22.51% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 32.84% ROE 06/30/25 - - 03/31/25 - -50.54 12/31/24 - -57.53 ROA 06/30/25 - - 03/31/25 - -37.19 12/31/24 - -43.36 Current Ratio 06/30/25 - - 03/31/25 - 5.91 12/31/24 - 6.10 Quick Ratio 06/30/25 - - 03/31/25 - 5.58 12/31/24 - 5.90 Operating Margin 06/30/25 - - 03/31/25 - -123.38 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - -123.38 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -123.38 12/31/24 - -258.64 Book Value 06/30/25 - - 03/31/25 - 32.01 12/31/24 - 34.59 Inventory Turnover 06/30/25 - - 03/31/25 - 0.41 12/31/24 - 0.49 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.17 12/31/24 - 0.16 Debt-to-Capital 06/30/25 - - 03/31/25 - 14.24 12/31/24 - 13.48

Powered by Zacks Investment Research ©